Workflow
Karyopharm Therapeutics(KPTI)
icon
Search documents
Karyopharm Therapeutics(KPTI) - 2023 Q4 - Annual Report
2024-02-29 12:43
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 KARYOPHARM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 26-3931704 (State ...
Karyopharm Therapeutics(KPTI) - 2023 Q3 - Earnings Call Transcript
2023-11-02 18:25
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President and CEO Reshma Rangwala - Chief Medical Officer Sohanya Cheng - Chief Commercial Officer Michael Mason - CFO Conference Call Participants Maury Raycroft - Jefferies Colleen Kusy - Baird Operator Good morning. My name is Guru and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Th ...
Karyopharm Therapeutics(KPTI) - 2023 Q3 - Quarterly Report
2023-11-02 11:57
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 26-393 ...
Karyopharm Therapeutics(KPTI) - 2023 Q2 - Earnings Call Presentation
2023-08-02 19:13
Second Quarter 2023 Financial Results & Business Update On Today's Call Elhan Webb, CFA, Senior Vice President, Investor Relations Richard Paulson, President and Chief Executive Officer • Commercial Highlights • Closing Remarks Richard Paulson, President and Chief Executive Officer This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's guidance on its 2023 total rev ...
Karyopharm Therapeutics(KPTI) - 2023 Q2 - Earnings Call Transcript
2023-08-02 18:55
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Elhan Webb - Senior Vice President, Investor Relations Richard Paulson - President and Chief Executive Officer Reshma Rangwala - Chief Medical Officer Sohanya Cheng - Chief Commercial Officer Michael Mason - Chief Financial Officer Conference Call Participants Kevin Strang - Jefferies Colleen Kusy - Baird Nicole Gabreski - Piper Sandler Brian Abrams - RBC Capital Markets Operator Good m ...
Karyopharm Therapeutics(KPTI) - 2023 Q2 - Quarterly Report
2023-08-02 11:48
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 26-3931704 ...
Karyopharm Therapeutics(KPTI) - 2023 Q1 - Earnings Call Transcript
2023-05-06 23:46
Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Reshma Rangwala - Chief Medical Officer Michael Mason - EVP, CFO & Treasurer Conference Call Participants Peter Lawson - Barclays Kevin Strang - Jefferies Colleen Kusy - Robert W. Baird Nicole Gabreski - Piper Sandler Eric Joseph - JPMorgan Operator Good morning. My name is ...
Karyopharm Therapeutics(KPTI) - 2023 Q1 - Quarterly Report
2023-05-04 12:04
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 26-3931704 ...
Karyopharm Therapeutics(KPTI) - 2022 Q4 - Annual Report
2023-02-17 12:34
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 KARYOPHARM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 26-3931704 (State or other jurisdic ...
Karyopharm Therapeutics(KPTI) - 2022 Q4 - Earnings Call Transcript
2023-02-15 17:10
Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) Q4 2022 Earnings Conference Call February 15, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Reshma Rangwala - Chief Medical Officer Michael Mason - EVP, CFO & Treasurer Conference Call Participants Peter Lawson - Barclays Bank Maurice Raycroft - Jefferies Nicole Gabreski - Piper Sandler & Co. Michael Ulz - Morgan Stanley Edward White - H.C. Wainwright & Co. Eric ...